Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Receives First Milestone in Roche Biomarker Collaboration

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.

The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended phase I oncology trial.

This is the first minor milestone achieved under the collaboration and licence agreement between Evotec and Roche, signed in 2011, which is part of the m4 Munich Biotech Cluster Personalized Medicine and Targeted Therapiesinitiative funded by the German Federal Ministry of Education and Research. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programmes for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.

Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Debiopharm Group™ to Collaborate
Innovative partnership based on Evotec’s Target X projects.
Wednesday, April 02, 2014
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
Evotec to apply integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Wednesday, November 24, 2010
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Evotec Extends Ongoing Collaboration with CHDI Worth up to US$ 37 Million
Three-year extension for integrated drug discovery support in the search of novel drug candidates for the treatment of Huntington Disease.
Tuesday, February 19, 2008
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!